View of Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn's Disease

Return to Issue Details Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn's Disease Download Download PDF